Ondansetron Fresenius Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Ondansetron Fresenius Kabi, is a 5‑HT3 receptor antagonist presented as a sterile injectable solution for intravenous administration. It is used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetron Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company ensures quality compliance with EU standards and provides reliable global logistics.

Ondansetron acts on the serotonergic pathway to control nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting (CINV): reduces incidence and severity of acute and delayed nausea. - Radiation‑induced nausea and vomiting (RINV): helps control nausea associated with radiotherapy. - Postoperative nausea and vomiting (PONV): prevents nausea and vomiting after surgical procedures.

Ondansetron may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Constipation - Diarrhea - Fatigue - Dizziness - Injection site reactions

Serious or Rare Side Effects: - QT interval prolongation - Serotonin syndrome - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmias - Hepatic dysfunction - Severe skin reactions (Stevens‑Johnson syndrome)

When prescribing ondansetron, clinicians should consider several safety measures.

- Assess cardiac risk: evaluate baseline ECG in patients with known QT prolongation. - Avoid concomitant use with other QT‑prolonging agents. - Monitor electrolytes: correct hypokalemia or hypomagnesemia. - Use with caution in hepatic impairment: dose adjustment may be needed. - Pregnancy and lactation: weigh benefits against potential risks. - Store at room temperature: keep in original container, protect from moisture and light.

Ondansetron can interact with a variety of medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Concurrent use with other QT‑prolonging drugs: may increase risk of torsades de pointes. - Combination with apomorphine: can cause severe hypotension and loss of consciousness. - Use with serotonergic agents (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Co‑administration with carbamazepine: may reduce ondansetron plasma levels. - Use with dexamethasone: may enhance anti‑emetic effect. - Concurrent use with anticholinergics: may increase constipation risk. - Interaction with oral contraceptives: may slightly increase plasma concentrations.